Triple Antagonist (Triple G)
Triple Hormone Receptor Agonist Research Compound
Triple Antagonist (Triple G) is an investigational triple hormone receptor agonist that simultaneously activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This 39-amino acid peptide linked to a C20 fatty diacid moiety represents the latest evolution in multi-receptor metabolic research — building on decades of work that progressed from single-receptor GLP-1 agonists through dual GIP/GLP-1 agonists to the current triple-receptor approach.
Why Researchers Study It
The progression from single to dual to triple receptor agonism is one of the clearest evolutionary arcs in metabolic peptide research. Adding glucagon receptor activation was counterintuitive — glucagon was traditionally associated with raising glucose levels. But published research has shown that combining it with incretin receptor agonism produces documented effects across multiple metabolic parameters. Phase 2 and Phase 3 clinical trial data have generated substantial interest.
Multi-Receptor Metabolic Signaling
Research has documented simultaneous GIP, GLP-1, and glucagon receptor activation — a novel approach targeting glucose homeostasis, appetite regulation, and energy expenditure.
Body Composition Research
Phase 2 trial data published in the New England Journal of Medicine documented dose-dependent changes in body weight and metabolic parameters over 48 weeks.
Hepatic Fat Studies
Research in Nature Medicine examined effects on hepatic fat content in subjects with metabolic dysfunction-associated steatotic liver disease.
Clinical Trial Progression
From Phase 1 through Phase 3 TRIUMPH trials, this compound has generated one of the most rapid clinical development timelines in metabolic peptide research.
Research Timeline
8 milestones spanning 2005–2025
- Evolution from single-receptor GLP-1 agonists to triple-receptor design (2005–2020)
- Phase 2 trial results published in the New England Journal of Medicine (2023)
- Phase 3 TRIUMPH-4 trial results demonstrated significant findings over 68 weeks (2025)
Related Learning
Guides, articles, and resources connected to this compound.
Triple-Receptor Metabolic Signaling
How multi-receptor agonism evolved from single to dual to triple activation.
Peptide Mechanisms Explained
Receptor binding, signaling cascades, and pathway interactions.
Complete Guide to Research Peptides
Comprehensive overview of the research peptide landscape.
How Peptides Work
Foundation guide covering peptide structure and signaling mechanisms.
Research Database
Searchable index of published research across all compounds.
Published Research
Selected citations from the published literature.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
PMID: 37366315Efficacy and safety of retatrutide for obesity treatment: systematic review and meta-analysis.
PMID: PMC12026077Nature Medicine. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. 2024. doi:10.1038/s41591-024-03018-2
Explore Triple Antagonist (Triple G)
Research data, product specifications, and related kits.
Research Use Compliance
All information presented on this page references published preclinical research and is provided for educational and informational purposes only. These products are intended for laboratory research use only. Not for human consumption. No statements on this page have been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.